NEO250117C13000
- 3.60
- 0.000.00%
NeoGenomics Newsroom
Raymond James Maintains NeoGenomics(NEO.US) With Hold Rating
Needham Maintains NeoGenomics(NEO.US) With Buy Rating, Maintains Target Price $19
Needham Reiterates Buy on NeoGenomics, Maintains $19 Price Target
NeoGenomics Analyst Ratings
Craig-Hallum Maintains NeoGenomics(NEO.US) With Buy Rating
Craig-Hallum Releases a Buy Rating on NeoGenomics (NEO)
NeoGenomics Is Maintained at Neutral by B of A Securities
BofA Securities Maintains NeoGenomics(NEO.US) With Hold Rating, Raises Target Price to $19
NeoGenomics Analyst Ratings
Jefferies Initiates NeoGenomics(NEO.US) With Buy Rating, Announces Target Price $22
A Quick Look at Today's Ratings for NeoGenomics(NEO.US), With a Forecast Between $18 to $21
A Quick Look at Today's Ratings for NeoGenomics(NEO.US), With a Forecast Between $18 to $20
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), NeoGenomics (NEO) and Ultragenyx Pharmaceutical (RARE)
NeoGenomics' Strong Financial Performance and Growth Potential Earns Buy Rating
Craig-Hallum Maintains NeoGenomics(NEO.US) With Buy Rating
Craig-Hallum Sticks to Their Buy Rating for NeoGenomics (NEO)
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), Trevi Therapeutics (TRVI) and DENTSPLY SIRONA (XRAY)
BofA Securities Maintains NeoGenomics(NEO.US) With Hold Rating, Announces Target Price $18
NeoGenomics Hold Rating Maintained Amidst Ongoing Legal Challenges and MRD Assay Development Uncertainty
Needham Maintains NeoGenomics(NEO.US) With Buy Rating, Maintains Target Price $19